ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Registrieren

Bereits Mitglied? Einloggen

Pepperstone

Jetzt Handeln

Pepperstone
Marktdaten
News
Werkzeuge
Märkte
Entdecken

Hot Features

Follow Feed

Vernetzen Sie sich mit Händlern und Investoren in unserer Follow-Feed-Community.

Optionen-Flow

Erkunden Sie umfassende Optionsdaten und nutzen Sie erweiterte Filter mit Options Flow.

Watchlist

Organisieren und überwachen Sie Ihre Aktien- und Vermögensbeobachtungsliste mit dem Monitor.
Anmelden Premium IconPremium Help Menu
DAX
18.704,42
-0,11%
S&P 500
5.303,27
0,12%
Dow Jones
40.003,59
0,34%
Euro vs US Dollar
1,08705
0,03%
Bitcoin
66.835,75
2,45%
Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.
Registrieren
  1. Startseite
  2. Investieren
  3. Aktien
  4. USA
  5. NASDAQ
  6. Moleculin Biotech Inc (MBRX)

  7. Moleculin Biotech Inc (MBRX) News

MBRX

Moleculin Biotech (MBRX)

Moleculin Biotech Inc
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:MBRX
DatumZeitQuelleÜberschriftSymbolFirma
16/05/202414h32Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBRXMoleculin Biotech Inc
16/05/202414h32PR Newswire (US)Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid CongressNASDAQ:MBRXMoleculin Biotech Inc
15/05/202414h38Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBRXMoleculin Biotech Inc
15/05/202414h38PR Newswire (US)Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06)NASDAQ:MBRXMoleculin Biotech Inc
14/05/202422h16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBRXMoleculin Biotech Inc
13/05/202416h53Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:MBRXMoleculin Biotech Inc
13/05/202413h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBRXMoleculin Biotech Inc
13/05/202413h30PR Newswire (US)Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:MBRXMoleculin Biotech Inc
10/05/202422h30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:MBRXMoleculin Biotech Inc
09/05/202414h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBRXMoleculin Biotech Inc
09/05/202414h30PR Newswire (US)Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for AnnamycinNASDAQ:MBRXMoleculin Biotech Inc
08/05/202414h45PR Newswire (US)Moleculin to Report First Quarter 2024 Financial Results on May 10, 2024 and Host Conference Call and WebcastNASDAQ:MBRXMoleculin Biotech Inc
08/05/202414h31Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBRXMoleculin Biotech Inc
07/05/202422h13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBRXMoleculin Biotech Inc
07/05/202414h55Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBRXMoleculin Biotech Inc
07/05/202414h55PR Newswire (US)Moleculin Reports Higher AML Complete Remission (CR) Rates and Significant Durability with Additional Interim Subject DataNASDAQ:MBRXMoleculin Biotech Inc
02/05/202415h00PR Newswire (US)Moleculin to Host Virtual AML Clinical Day Featuring Internationally Renowned Clinician, Martin S. Tallman, MD, on May 7, 2024NASDAQ:MBRXMoleculin Biotech Inc
01/05/202414h50PR Newswire (US)Moleculin Announces Formation of Scientific Advisory Board to Support Development of AnnamycinNASDAQ:MBRXMoleculin Biotech Inc
18/04/202414h30PR Newswire (US)European Medicines Agency (EMA) Grants Orphan Drug Designation for Moleculin's Treatment of Acute Myeloid Leukemia (AML)NASDAQ:MBRXMoleculin Biotech Inc
10/04/202414h30PR Newswire (US)Moleculin Announces Presentation of Positive Data Demonstrating High Anti-Cancer Activity of Annamycin and Non-Cardiotoxic PropertiesNASDAQ:MBRXMoleculin Biotech Inc
28/03/202415h45PR Newswire (US)Moleculin to Present at the MedInvest Biotech & Pharma Investor ConferenceNASDAQ:MBRXMoleculin Biotech Inc
27/03/202414h25PR Newswire (US)Moleculin to Participate in the Virtual Investor Lunch Break: The Moleculin OpportunityNASDAQ:MBRXMoleculin Biotech Inc
27/03/202414h05PR Newswire (US)Moleculin Announces U.S. Patent Issue Notification for Annamycin Targeting Unmet Need in AMLNASDAQ:MBRXMoleculin Biotech Inc
25/03/202412h30PR Newswire (US)Moleculin Announces Positive Interim Data in Annamycin MB-106 Phase 1B/2 AML TrialNASDAQ:MBRXMoleculin Biotech Inc
22/03/202421h05PR Newswire (US)Moleculin Reports Full Year 2023 Financial ResultsNASDAQ:MBRXMoleculin Biotech Inc
20/03/202412h30PR Newswire (US)Moleculin to Report Full Year 2023 Financial Results on March 22, 2024 and Host Conference Call and WebcastNASDAQ:MBRXMoleculin Biotech Inc
20/03/202412h15IH Market NewsJPMorgan boosts dividends, Chipotle unveils 50:1 stock split, and Latest NewsNASDAQ:MBRXMoleculin Biotech Inc
19/03/202421h30PR Newswire (US)Moleculin Announces Reverse Stock SplitNASDAQ:MBRXMoleculin Biotech Inc
12/03/202414h05PR Newswire (US)Moleculin to Present at the 36th Annual ROTH ConferenceNASDAQ:MBRXMoleculin Biotech Inc
29/02/202414h30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:MBRXMoleculin Biotech Inc
 Showing the most relevant articles for your search:NASDAQ:MBRX

Kürzlich von Ihnen besucht

COIN
KUJIETH
Kuji
BIT
UB82E5
Unicredit Bank
Delayed Upgrade Clock
ADVFN Logo

Deutschland
Unternehmen
Geschäft
Popular
App herunterladen

Support: +44 (0) 203 8794 460 | support@advfn.de

Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen

© 2024 ADVFN PLC - Alle Rechte vorbehalten